Tag
Elon Musk comments that Ashlee Vance's 10,000-word feature on Neuralink and 'The Merge' is probably about 80% accurate, despite not having read it.
San Francisco startup Loyal is close to FDA approval for the first drug ever designed to extend healthy lifespan in senior dogs, a daily beef-flavored chew targeting the metabolic side of aging, with manufacturing review expected in 2027 and pricing aimed under $100/month.
Scientists in Tanzania's Transmission Zero project gene-edited mosquitoes using molecules from frogs and honeybees to block malaria parasite growth, with results published in Nature. The edited trait is paired with a gene drive so it spreads to over 90% of offspring, potentially letting the malaria block take over wild mosquito populations within a few generations.
A virus injection therapy halted pancreatic cancer in three patients, offering a promising new approach against one of the deadliest cancers.
MIT Technology Review's daily Download newsletter covers a human liver kept alive for seven weeks, Sila's billion-dollar silicon-anode deal with Panasonic Energy, and the latest AI Hype Index, plus Anthropic's record $81 billion IPO raise.
In its podcast, Google DeepMind introduces Alpha Genome 2, advancing AI's ability to read genomes down to the level of individual cell types — enabling researchers to score and rank the impact of single DNA mutations and to pinpoint truly noteworthy variants across the 98% of the non-coding genome.
Nitroduck, founded by plant synthetic biologists and iGEM Grand Prize winners, is launching a CRISPR-based crop design platform that delivers gene edits via pollen grains instead of stem cells, aiming to make any crop gene-editable and eventually obsolete pesticides by 2042.
Y Combinator highlights how engineering skills translate to founding startups, featuring Shivani Patel and Chris Markus of Layers Bio and BootLoop AI, both SpaceX alumni taking ideas from zero to one.
The FDA is moving to withdraw approval of Amgen's vasculitis drug Tavneos after evidence emerged that ChemoCentryx manipulated data in its pivotal trial, leading to a NEJM retraction and market removals in the EU and UK, while Amgen fights to keep the drug on the US market.
Biotech founder Gabriel Ocana Santero of Exin Therapeutics connected an AI agent to a robotic surgical rig, allowing Claude Sonnet 5 to autonomously perform a brain injection on a live mouse with epilepsy after Claude Opus 5.5 refused to carry out the procedure, showcasing AI's emerging role as an active participant in laboratory research.
@muni_bio 和 @onepot_ai 于七月联合举办 Ebolathon,团队在一天内设计出 140 个靶向 Bundibugyo 埃博拉病毒进入细胞的小分子,经合成与测试后获得 18.6% 的初步命中率,部分流程由 Modal 提供算力支持。
Superpower announces Superpower Peptides, a prescription peptide care service pairing clinician-prescribed peptides like BPC-157, TB-500 and MOTS-c with comprehensive blood testing, monitoring, and membership, with pre-orders open and shipping targeted for late November.
MIT Technology Review's daily newsletter covering GLP-1 drugs' link to rising eating disorders, a short story about self-aware cities, PFAS cleanup efforts, and the largest crypto hack in history at Binance.
一篇 MIT Technology Review 报道指出,全球厌食症和暴食症发病率在1990至2023年间上升71%,临床医生发现GLP-1减重药物正被部分患者滥用,可能加剧饮食失调问题。
The tweet describes Mithril, an extremely lean, virtually operated drug R&D company that has sustained its operations through a model of “one operator + extensive use of Claude AI + part-time consultants,” evolving into an experiment in how far an individual can advance a drug R&D company with the help of AI.
Anthropic acquired Mithril Medicine, a biotech company with only one full-time employee, which relies on Claude and part-time consultants to drive drug development and is seen as an early sample of AI changing the way biopharma is organized.
Elon Musk tweeted that breakthroughs across all fields are accelerating exponentially, quoting a post claiming a massive, under-reported shift in human biology driven by biotech advances.
Commentary arguing that as AI makes drug discovery cheap, clinical trials and patient biology data become the bottleneck, highlighting tech giants like Anthropic and OpenAI moving into AI-driven drug development and biotech acquisitions.
A Verge Optimizer column examines the red flags in the new laser-based diagnostics venture Haemanthus, dubbed 'Theranos 2.0,' as depicted in Nathan Fielder's documentary, offering guidance on spotting health-tech hype versus real science.
Anthropic used its Claude model in partnership with Divergence Labs to generate around 35,000 antibody designs in weeks, with some candidates outperforming Xolair at dislodging cell-bound IgE in lab tests, accelerating food allergy treatment research.